Plus Therapeutics introduced its CNSide cerebrospinal fluid diagnostics platform into the U.S. market, secured a first national coverage agreement with UnitedHealthcare effective September 15, 2025, and reported positive Phase 1 data for its leptomeningeal metastases radiotherapeutic, Reyobiq. The company also achieved CLIA certification for its Houston lab, expanded its commercial team, and ended Q3 with $16.6 million in cash and investments, buoyed by an additional $1.9 million advance from the Cancer Prevention and Research Institute of Texas and regained compliance with Nasdaq listing standards.
The strategic throughline is hard to miss: Plus is building an integrated LM franchise where a reimbursed LDT drives identification, monitoring, and treatment decisions that funnel directly into a proprietary CNS radiotherapeutic. For a small cap radiopharma developer, owning a payer-backed diagnostic at launch is more than a side business—it is a market-making asset that can de-risk development, accelerate enrollment, and condition prescriber behavior ahead of a potential therapeutic approval. The operative question is whether CNSide becomes a de facto companion diagnostic that tightens the evidence loop between molecular monitoring and response to localized beta-emitting therapy.
For patients and neuro-oncologists facing the grim realities of LM, the potential impact is immediate. The retrospective analysis of 613 CNSide assays suggests the platform can quantify disease burden over time and track actionable mutations in CSF, offering clinicians a way to adapt therapy to dynamic tumor biology. If the RESPECT-LM Phase 1 single-dose escalation data—feasibility, favorable safety, and an emerging efficacy signal—translate into a registrational design, CSF-guided care could move from aspirational to operational. Payers will watch for real-world evidence showing that serial CNSide testing meaningfully changes management and outcomes; UnitedHealthcare’s early national coverage opens access for 51 million lives, but broad adoption will require clear utilization criteria, coding expansion, and, critically, Medicare alignment.
Commercially, Plus is starting where LM patients concentrate: NCI-designated cancer centers, particularly those already familiar with CNSide. That focus should help the company seed high-yield sites for clinical development of Reyobiq, a rhenium-186 based therapy with intrinsic imaging capability for procedure guidance and response assessment. If Plus can tie CNSide-derived biomarkers to Reyobiq outcomes, Medical Affairs will have a powerful narrative for HCP education and payer dossiers, and the company could shorten the evidence cycle between trial data and real-world practice.
The move also reflects broader currents reshaping oncology. Radiopharmaceuticals are in a renaissance, with investors and strategics pursuing platform plays that combine targeted delivery, imaging, and increasingly, diagnostics. Meanwhile, the regulatory landscape for LDTs is tightening, pushing labs to secure CLIA credentials, quality systems, and payer contracts earlier. Plus is threading that needle by anchoring CNSide in a certified lab with national coverage, while funding development through a mix of non-dilutive grants and opportunistic equity—an increasingly common blueprint for CNS-focused biotechs navigating a cautious capital market.
What comes next will determine whether this integrated model scales. FDA feedback on the pivotal plan for Reyobiq in LM, expansion of CNSide beyond Texas into a national footprint, and generation of prospective RWE linking CSF dynamics to clinical benefit are the near-term catalysts. If Plus can convert diagnostic touchpoints into therapeutic adoption, the company may set a template for CNS oncology: win payer coverage for the test first, then let the data pull the therapy through. The open question is whether larger radiopharma and neuro-oncology players let that template remain independent for long.
Source link: https://www.globenewswire.com/news-release/2025/10/30/3177957/0/en/Plus-Therapeutics-Reports-Third-Quarter-Financial-Results-and-Recent-Business-Highlights.html
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
